Mimetics of antibody-binding sites represent particularly interesting targets, however they are difficult to identify. In most cases, naturally derived CDR3 peptides show a much lower activity and affinity. In this study, we identified a CDR3 domain antibody with framework 3 (FR3) and FR4 in the flank by screening a lysozyme-immunized phage display VHH library. This antibody has a potent enzyme inhibiting activity and high thermal stability. With sequence alignment and sitedirected mutagenic analysis, we found that the cysteine residue at amino acid position 88 in FR3 might play a key role in maintaining the stability of the CDR3 antibody. The small-sized CDR3 domain antibody might act as a new scaffold for affinity transfer, hence making a useful contribution to the understanding of antigen-antibody interactions.
Introduction
The poor penetration of native antibodies and their high cost of production have inspired the search for smaller alternatives. In recent years, gene technology has been successfully applied in cloning and engineering of smaller fragments of antibody genes, such as Fab fragment, VH single domain and single-chain Fv fragment (scFv). Unfortunately, the scFv molecules usually have reduced affinity when compared with their parent antibodies, and the linker sequences frequently lead to aggregation of scFv and can be easily degraded by proteolysis. Moreover, the production of single-domain VH antibodies has been proved to be unsuccessful because the isolated VH molecules are 'sticky' and mostly insoluble. Therefore, molecules with higher stability and smaller size remain to be developed to optimize the antibody's performance.
Although it is commonly accepted that antigen recognition by whole antibodies requires multiple noncovalent forces involving all six CDR loops residing in the VH and VL domains, some researchers have demonstrated that synthetic peptides derived from the amino acid sequences of CDRs can retain antigen-binding abilities [1] [2] [3] [4] [5] . Within the antigen-binding site, the H3 loop is the major determinant of antibody diversity and the major contributor for the overall antigen affinity and specificity [6, 7] . Therefore, most antibody mimetics are derived from CDR3 sequences. However, in most cases, CDR-derived peptides show a much lower activity and affinity, even though their bioactivities may be comparable to those of their parent antibodies in a few cases [8] .
In general, functional immunoglobulins (IgGs) always comprise two heavy and two light chain, but natural IgG antibodies devoid of light chains (referred as heavy-chain antibodies, HCAbs) have also been discovered in camelids [9] . The variable domain of a camel heavy-chain antibody (termed VHH) can be routinely recovered by phage display technique, and the structures of these loops differ significantly from those of mammalian VHs but maintain full antigenbinding activities. In addition, the CDR3 loop of the VHH domain is significantly larger than those in mouse and human VHs, which increases the antigen-binding surface relative to that of VH and partially compensates for the lack of the light chain. For example, in the camel VHH/lysozyme complex, contact is essentially made via a long CDR3 loop of 27 residues [10] . Another difference between classical VH and camel VHH is the frequent occurrence of an additional disulfide bridge between CDR1 and CDR3 in VHH, which probably restrains the flexibility of the CDR3 loop of a VHH, providing a more hydrophilic surface leading to increased solubility and stability of the antibody structure.
The key role of CDR3 loop in VHH raised the interests on the antigen-binding activity of synthetic peptides derived from the structure. In some studies, lysozyme was employed as the model antigen, and a few VHHs were found to act as potent enzyme inhibitors by mimicking an oligosaccharide substrate [11] . For example, a singledomain antibody cAbLys3 was well-characterized in structure and its CDR3 region was found to form an exposed loop of 24 amino acids that fits tightly into the active site cleft of lysozyme. Furthermore, the synthesized peptide with the original 24 amino acid residues directly from cAbLys3 CDR3 loop was found to have high native-like affinity to the active site of lysozyme [12] . These results highlight the possibilities that a single synthetic CDR3 peptide can essentially maintain the antigen recognition of a complete camel heavy-chain antibody, even though it comprises a relatively short sequence.
In this study, we identified a CDR3 domain antibody with framework 3 (FR3) and FR4 in the flank by screening a lysozymeimmunized phage display VHH library and found that a natural VHH CDR3 fragment exists in the camel immune repertoire which can act as a potent enzyme inhibitor.
Materials and Methods

Camel immunization and library construction
A four-year old female camel (Camelus bactrianus) was immunized by five intra-dermal injections of 0.2 ml lysozyme (1 mg/ml; Sigma, St Louis, USA) mixed with an equal volume of Freund's complete adjuvant in the pre-scapular region, followed by four booster injections with Freund's incomplete adjuvant every 2 weeks. The blood of immunized animal was collected centrifuged, and the sera were stored in aliquots at −20°C. Peripheral blood lymphocytes were obtained by centrifugation on a Ficoll-Paque (GE Healthcare, Chicago , USA), and stored at −80°C until further use. The total serum IgG of immunized camel on Day 70 was measured by ELISA as described previously [13] . Lymphocytes obtained from immunized camel on Day 70 were used for library construction. The cDNA was first synthesized by reverse transcription from total RNA of immunized camel lymphocytes using oligo-dT primers. The sets of primers used for amplification of VHH coding domain and part of the hinge region DNA were described in our previous report [13] . VHH libraries were constructed in the pCANTAB 5E phagemid vector (GE Healthcare) which was slightly modified by substitution of NotI cutting sequence (GCGGCCGC) with SfiI sequence (GGCCTCGGGGGCC). The VHH repertoire was expressed on phage after infection with M13K07 helper phages (GE Healthcare).
Selection and enrichment of lysozyme-specific VHHs
Approximately 1 × 10 9 Escherichia coli TG1 cells were grown in 2 × YT to mid-logarithmic phase before infection with M13K07. Virions were precipitated from culture supernatant with 20% PEG 8000 and 2.5 M NaCl, and then resuspended in sterile PBS and used for panning at a titer of 10 13 /ml. A Maxisorb 96-well microtiter plate (NUNC, Rochester, USA) was used for bio-panning. The wells were blocked with PBST + 3% BSA at 37°C for 2 h and then washed three times with PBST, followed by the addition of 2 × 10 13 phages for panning. During panning, specific VHHs against lysozyme were enriched by four consecutive rounds of in vitro selection on 96-well microtiter plates coated with antigen of descending concentrations (1, 0.25, 0.10, and 0.05 mg/ml), and 100 μl of sodium bicarbonate buffer was used as negative control. A total of 10 μl of eluted phages (output; 10 folds serially diluted) were used to infect log phase E. coli TG1 for the detection of the titers of phage particles in input and output at all steps. The enrichment of phage particles carrying antigen-specific VHHs were assessed by comparing results of input phages and output phages. The rest of eluted phages were also used to infect 5 ml of E. coli TG1 for phage amplification. The output phages were rescued using the M13K07 helper phage. The phages were precipitated with 20% PEG/NaCl, and the phage particles were collected by centrifugation, resuspended in PBS, and stored at −20°C (input). Panning was carried out as mentioned above for four consecutive rounds. To monitor the success of panning process, polyclonal phage ELISA was performed on phages eluted after each round of panning. About 10 12 cfu of output phages and output phages from each round of panning were used to perform polyclonal phage ELISA. An anti M13-HRP antibody (1:2500; GE Healthcare) was used to detect the binding phages. Absorption of each well was measured at 450 nm with a microplate reader.
Expression and purification of recombinant VHHs
The VHHs genes of the clones that scored positive in ELISA were subcloned into the pET22b(+) expression vector between NcoI and XhoI sites and expressed in E. coli BL21 (DE3) cells via standard cloning techniques. The transformed bacteria were grown in 500 ml LB-ampicillin culture flasks until the absorbance at 600 nm reached a value between 0.6 and 0.9. The VHHs expressions were then induced with 1 mM isopropyl-thiogalactopyranoside for at least 5 h at 25°C. After cells were collected, the periplasmic proteins were extracted by osmic shock. This periplasmic extract or inclusion body was loaded on a Ni Sepharose 6 Fast flow column (GE Healthcare). After extensive wash, the bound proteins were eluted with elution buffer (20 mM sodium phosphate, pH 7.4, containing 0.5 M NaCl and 500 mM imidazole). The purity of recombinant VHHs was evaluated by SDS-PAGE (12% acrylamide) and Coomassie brilliant blue staining.
Antigen binding and thermal stability of VHH domains evaluated by ELISA Lysozyme (2 μg/ml) was coated onto the wells of microtiter plates at 4°C overnight. An unrelated antigen allinase (2 μg/ml) was coated as negative control. Wells were blocked with PBS-skimmed milk 3% (200 μg/well) and incubated with the lysozyme-specific VHHs or VHHA4 (an unrelated antibody which specifically binds allinase) in 1% skimmed milk-PBS. After three times of wash, the bound VHHs were detected with anti-His tag antibody conjugated with HRP. Peroxidase enzyme activity was determined after addition of TMB as substrate and measured at 450 nm. The thermal stability of VHHs was determined by detecting the residual lysozyme-binding activities before and after heat treatment. The percentage of residual activity (RA%) was calculated by the following equation: RA% = [1 -(OD 450 -OD 450 heat) / (OD 450 )] × 100%. A mouse anti-lysozyme mAb NYRHEL (Santa Cruz Biotech, Santa Cruz, USA) was used as control. In brief, nanobodies (10 μg/ml) and NYRHEL (1:500) were incubated for 30 min at increasing temperatures (4°C, 15°C, 22°C, 37°C, 50°C, 60°C, 70°C, 80°C, and 90°C) and then re-equilibrated to room temperature before measuring residual lysozyme-binding activity. The color development and OD measurement were performed as described above.
Evaluation of nanobody binding epitopes with competitive ELISA
A 96-well plate was coated with lysozyme (2 μg/ml) at 4°C overnight. Equal amount of lysozyme specific nanobodies (2 μg) and a mouse anti-lysozyme mAb NYRHEL (1:2000; Santa Cruz Biotech) were added alone or in combination with a lysozyme inhibitor N-acetyl-D-glucosamine (1 μM; Sigma). An unrelated nanobody VHHA4 was used as negative control. The plate was incubated for 1 h at room temperature and washed with PBST. The bound VHHs or mAb were detected with anti-His tag antibody conjugated with HRP or goat anti-human IgG-HRP antibody (Santa Cruz Biotech; 1:2000) for 1 h at room temperature. After extensive wash, the assay was developed with TMB and the OD value was measured at 450 nm.
Inhibition of lysozyme activity by VHHs
The inhibitory activity of VHHs against lysozyme was determined as previously described [14] . In brief, various concentrations of lysozymespecific nanobodies and an unrelated nanobody VHHA4 were preincubated with lysozyme (10 μg/ml) for 1 h at 25°C in 300 μl of phosphate buffered saline (pH 6.24) in a 96-well plate. After the addition of 50 μl Micrococcus lysodeikticus (180 μg/ml, previously incubated at appropriate temperature), the initial rate of hydrolysis was measured as the decrease in absorbance at 450 nm using a microtiter plate reader. The 50% inhibitory concentrations (IC 50 ) were obtained by plotting lysozyme residual activity as a function of increasing antibody fragment concentration. A minimum of six replicates per measurement were performed for each antibody fragment concentration, and two independent series of measurements were conducted for each condition.
Site-directed mutagenesis and VHH NbL42 variants generation
The glutamic acid (E) residue at amino acid position 71, serine (S) residue at position 79, and cysteine (C) residue at position 88 of VHH NBL42 were mutated to valine (V), proline (P), and tyrosine (Y), respectively by site-directed mutagenesis introduced by PCR with primers containing mutated codons at indicated position, and the variants are denoted as NbL42-E71V, NbL42-S79P, and NbL42-C88Y. The DNA sequences of each mutant were ligated into a pET22b(+) expression vector and transformed into E. coli BL21 (DE3) cells. The expression and purification of the variants were performed as described above.
Results
VHH phage display library construction and enrichment of lysozyme-binding ligands
The lysozyme-specific humoral response of the immunized camel was raised and the titer of sera reached 1:25,600 after the last immunization. A VHH phage display library contained 2.8 × 10 5 individual clones was constructed and identified as described previously [13] . Four rounds of panning were performed on the microtiter plates. The enrichment of antigen-specific clones during the consecutive rounds of panning was assessed by phage ELISA on coated lysozyme upon addition of a fixed amount of virions (10 12 ) per well. Enrichment experiments showed a significant increase in the ratio of phage particle after each round of panning by comparing with the titer of phage particle in the positive wells coated with lysozyme antigen and negative wells coated with BSA antigen ( Table 1) .
The enrichment ratio was increased by 14.28 folds after the fourth round of biopanning. Polyclonal phage ELISA confirmed specific binding of each eluted phage from different rounds of biopanning. The highest enrichment occurred in the third and fourth rounds of biopanning (Fig. 1) . After the fourth round of panning against lysozyme, 28 colonies were randomly selected for sequencing. The VHH clones derived from the library were named NbLx. The 28 colonies represent 14 distinct individuals, in which nine clones encoded NbL114, six clones encoded NbL23 and two clones encoded NbL42. The other 11 clones encoded the single VHH gene individually. The deduced amino acid sequences of the 15 lysozyme-specific VHH fragments were aligned using multiple sequence alignment program ClustalX2.1 against the human VH consensus sequence (Fig. 2) . The sequence homology of these clones with germlines was analyzed by using IgBLAST at the National Center for Biotechnology Information (http://www.ncbi.nlm. nih.gov/igblast/).
Sequence analysis of the heavy-chain genes revealed that all of the most similar germ line of V-segments belonged to the VH3 family (VH3-9, VH3-11, VH3-20, VH3-23, or VH3-66). Regarding the VHHs retrieved from the library, it is very clear that almost all but the NbL10 and NbL22 clones were derived from heavy-chain antibodyspecific VHH germ line genes, as they all contain the hallmark amino acid substitutions in framework 2 (V42Y/F, G49E, L50R, and W52Xaa) based on the IMGT numbering system [15] . This region is hydrophilic in VHHs, in contrast to the hydrophobic region in the VH. These amino acids are essential to avoid the association with the VL.
Sequence analysis of a CDR3 only VHH antibody
Among the selected 30 clones sequenced, one clone, namely NbL42 which comprises only CDR3 and the FR3-FR4 framework, was retrieved from the library unexpectedly. Analysis of the amino acid (AA) mutations in FR3 with IMGT/V-QUEST analysis tool [16] ( Table 2 and Fig. 3) showed that there are 12 mutations (V71E, T77I, S79P, S83A, L87V, Y88C, M91L, R95E, A96T, E97D, T99M, and V101T) when compared with the human V-REGION of the closest germline V-GENE. In comparison with the FR3 sequences in VHHs V-REGION of the 156 available VHH sequences (87 from Camelus dromedarius, 61 from C. bactrianus and 8 from Lama glama) retrieved from IMGT-DB, the sequence of FR3 in NbL42 showed three unusual mutations, i.e. V71E, S79P, and Y88C ( Supplementary Fig. S1 ), and lacked the first four amino acids (YYAD) in FR3 region.
Identification and characterization of a CDR3 only VHH antibody
According to the deduced amino acid sequences, clone NbL23, NbL42, and NbL114 specific to lysozyme were selected and subcloned into an expression vector pET22b(+) for expression. The induced recombinant proteins were expressed in E. coli and purified from bacterial periplasmic extracts by immobilized Ni-NTA-affinity chromatography. The purity of the products is more than 95% as demonstrated by SDS-PAGE and Coomassie brilliant blue staining (Fig. 4A) . The NbL42 and NbL114 were expressed as soluble proteins in the periplasm of E. coli, while NbL23 was expressed as inclusion body. The specific binding of VHHs to lysozyme was confirmed by ELISA (Fig. 4B) , which showed that NbL42, NbL23 and NbL114 had similar lysozyme binding activity, and had no cross reactivity with other antigens (Fig. 4B) . To determine the thermal stability of VHHs, a standard indirect ELISA was performed to test whether the binding could be observed at increased temperatures. As shown in Fig. 4C , NbL23, NbL42, and NbL114 retained 95%, 61%, and 46% antigen binding activities respectively after incubation at 90°C for 30 min. In contrast, the mAb NYRHEL showed almost no antigen binding activity when the temperature was above 80°C. The CDR3 only VHH antibody NbL42 showed high thermal stability compared with conventional antibody.
Inhibitory effect of NbL42 on lysozyme
Competitive binding between lysozyme-specific antibodies (NbL23, NbL42, NbL114, and NYRHEL) and N,N',N'-triacetylchitotriose (GlcNAc) 3 , a substrate analog that binds reversibly to the enzyme [17] , was investigated by competitive ELISA. Figure 5A shows that in the Reactivity of nanobodies (10 μg/ml) was tested with indirect ELISA against lysozyme (5 μg/ml) and BSA. An allinase-specific nanobody VHHA4 was used as negative control. (C) Thermal stability of NbL42 was compared with two VHHs and one commercially available mouse monoclonal anti-lysozyme antibody NYRHEL. Antibodies were incubated at increasing temperatures for 30 min, re-equilibrated to room temperature, and then assayed in the standard lysozyme-specific ELISA. The values are the mean of three independent determinations.
presence of (GlcNAc) 3 , the binding level of NbL23, NbL42, and NbL114 with lysozyme decreased by 51%, 37%, and 34%, respectively, indicating that the nanobodies are competitive inhibitors of the enzyme, which can bind to the active site of the protein. In contrast, the binding of mAb NYRHEL with lysozyme was not influenced by addition of (GlcNAc) 3 . The inhibitory activities of the nanobodies were measured by residual enzymatic activity in an enzyme/Ab mixture (Fig. 5B) , and the IC 50 was determined. The IC 50 values for NbL23, NbL42, and NbL114 were 9.05, 7.06, and 8.7 μg/ml, respectively. Under the same conditions, the IC 50 for (GlcNAc) 3 is 3.75 μg/ml. This result indicates that NbL42 acts as a good inhibitor of lysozyme.
Cysteine residue plays an important role in stabilizing NbL42 peptide antibody
To evaluate the effects of mutated amino acids on nanobody NbL42 FR3 region, three variants NbL42-E71V, NbL42-P79S, and NbL42-C88Y were generated by site mutagenesis. The substitution of residues 71 and 79 led to decreased antigen binding activities but without interference with their soluble expression in E. coli. In contrast, the substitution of residues 88 with Cys led to a complete loss of antigen binding activity and no soluble expression in E. coli (Fig. 6A) . The inhibitory activity of the NbL42 variants was also decreased. The IC 50 values for NbL42-E71V and NbL42-P79S were 30.06 and 45.5 μg/ml, respectively (Fig. 6B) . These results indicated that the cysteine 88 residue plays an important role in maintaining antigen binding.
Discussion
In this study, we selected nanobodies that bind to the active site of lysozyme. Especially, one of nanobody NbL42, with only one CDR region but has complete lysozyme-binding activity was selected from VHH library. Moreover, the CDR3 only peptide antibody possesses a potent lysozyme-inhibiting activity. As far as we know, this is the first report of CDR3 only nanobody with good antigen-binding activities and enzyme-inhibiting activities.
Mimetics of antibody-binding sites represent a particularly interesting target but have been proved to be difficult to identify. The reason may be that the potential small mimetics do not mimic the conformation of the CDR sufficiently, and effective IgG binding requires more than one CDR or the mass of the IgG is essential to its biological activity. Several approaches have been tried to simplify the problem by targeting the mimetic design to CDR H3, since this CDR is typically at the center of most, if not all, antigen interactions [18] . But so far only a few CDR3-derived antibody mimetics have been generated [2] [3] [4] [5] 8, 12] . In this study, a CDR3 only peptide antibody with flanked FR3 and FR4 structure was unexpectedly retrieved from a lysozyme immunized camel VHH library. Unlike artificially synthesized CDR3 mimetics, NbL42 derived from the natural source might be generated during the somatic hypermutation. The remarkable differences among other VHHs are the unusual mutations of V71E, S79P and Y88C, the lack of the first four amino acids (YYAD) in FR3 region, and the complete loss of CDR1, CDR2 and their framework regions. Based on the potent antigen-binding and enzyme-inhibiting activities of NbL42, it is reasonable to infer that the FR3 region plays a critical role in supporting the stable structure of the antibody. From the 156 VHHs sequences ( Supplementary  Fig. S1 ), no cysteine residue was found at this position. Examination of more VHH and VH sequences (data not shown) revealed that except the conserved position 104, the cysteine residue present at FR3 region of VHH was rarely seen. An important hallmark of the immunoglobulin folding is the conserved disulfide bond located between cysteines of β-strands B and F at amino acid positions 23 and 104 [19] . The importance of this conserved cysteine for folding and intrinsic stability of the immunoglobulin domain has been well established. In addition, it was noticed that many VHHs of camel heavy chain antibody possess an additional disulfide bond between the complementarity-determining region-1 (CDR1) and CDR3 loops [20, 21] , suggesting that the interloop disulfide bond can stabilize the domain and rigidify the long third antigen-binding loop, leading to a stronger antigen interaction by cysteines connecting antigen-binding loops in single domain antibodies. The mutagenesis assay of the above three NbL42 variants showed that the cysteine residue at position 88 might also play a key role in supporting the platform for accommodating the antigen-binding loops, because the antigenbinding and enzyme-inhibiting activities were almost lost in the C88Y mutant. Other unusual amino acid residues E71 and P79 in FR3 might play a rather weak role in the antigen-binding and enzyme-inhibiting activity of NbL42.
Development of the universal VHH framework to graft various CDR3 loops of VHHs for the rapid generation of antigen-specific antibody is still a challenge. Saerens et al. [22] identified the framework of cAbBCII10 as a potential universal VHH framework to graft various loops of VHHs of subfamily 2. This antibody comprises the intact VHH sequence, and the functional grafted VHH antibody requires three CDRs transfer of antigen specificity from donor VHHs onto its scaffold. This may restrict most CDR sequence grafting to generate functional VHHs. Whether our CDR3 only VHH framework (NbL42) can be used as a potential universal VHH framework for easily grafting various loops of VHHs deserves further exploration. Nevertheless, the CDR3 only peptide antibody has the advantage of small size, which facilitates the structure-function analysis. It will contribute to the understanding of antigen-antibody interactions.
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